Publications

Select Publications (1999 - present)

Bhattacharya A, Tóth K, Durrani FA, Cao S, Slocum HK, Chintala S, Rustum YM. Hypoxia-specific drug tirapazamine does not abrogate hypoxic tumor cells in combination therapy with irinotecan and methylselenocysteine in well-differentiated human head and neck squamous cell carcinoma A253 xenografts. Neoplasia 2008;10(8):857-65.

Chandrasekaran EV, Xue J, Piskorz C, Locke RD, Tóth K, Slocum HK, Matta KL. Potential tumor markers for human gastric cancer: An elevation of glycan:Sulfotransferases and a concomitant loss of α1,2-fucosyltransferase activities. Journal of Cancer Research and Clinical Oncology 2007;133(9):599-611.Azrak RG, Frank CL, Ling X, Slocum HK, Li F, Foster BA, Rustum YM. The mechanism of methylselenocysteine and docetaxel synergistic activity in prostate cancer cells. Molecular Cancer Therapeutics 2006;5(10):2540-8.

Dennis CG, Greco WR, Brun Y, Youn R, Slocum HK, Bernacki RJ, Lewis R, Wiederhold N, Holland SM, Petraitiene R, Walsh TJ, Segal BH. Effect of amphotericin B and micafungin combination on survival, histopathology, and fungal burden in experimental aspergillosis in the p47 phox-/- mouse model of chronic granulomatous disease. Antimicrobial Agents and Chemotherapy 2006;50(2):422-7.

Gibbs JF, Rustum YM, Slocum HK. Image analysis using the fluorochromasia assay to quantify tumor drug sensitivity. Methods in Molecular Medicine. 2005;110:185-95.

Ramnath N, Khushalani N, Toth K, Litwin AM, Intengan ME, Slocum HK, Pendyala L, Smith PF, Stewart CC, Hoffman JL, Javle MM, Berdzik J, Creaven PJ, Rustum YM. S-phase modulation by irinotecan: Pilot studies in advanced solid tumors. Cancer Chemotherapy and Pharmacology 2005;56(5):447-54.

Ling X, Yang J, Tan D, Ramnath N, Younis T, Bundy BN, Slocum HK, Yang L, Zhou M, Li F. Differential expression of survivin-2B and survivin-ΔEx3 is inversely associated with disease relapse and patient survival in non-small-cell lung cancer (NSCLC). Lung Cancer 2005;49(3):353-61.

White DB, Faessel HM, Slocum HK, Khinkis L, Greco WR. Nonlinear response surface and mixture experiment methodologies applied to the study of synergism. Biometrical Journal 2004;46(1):56-71.

Bhattacharya A, Tóth K, Mazurchuk R, Spernyak JA, Slocum HK, Pendyala L, Azrak R, Cao S, Durrani FA, Rustum YM. Lack of microvessels in well-differentiated regions of human head and neck squamous cell carcinoma A253 associated with functional magnetic resonance imaging detectable hypoxia, limited drug delivery, and resistance to irinotecan therapy. Clinical Cancer Research 2004;10(23):8005-17.

Aljada IS, Ranmath N, Donohue K, Harvey S, Brooks JJ, Wiseman SM, Khoury T, Loewen G, Slocum HK, Anderson TM, Bepler G, Tan D. Upregulation of the tissue inhibitor of metalloproteinase-1 protein is associated with progression of human non-small-cell lung cancer. Journal of Clinical Oncology 2004;22(16):3218-29.

Deeb G, Wang J, Ramnath N, Slocum HK, Wiseman S, Beck A, Tan D. Altered E-cadherin and epidermal growth factor receptor expressions are associated with patient survival in lung cancer: A study utilizing high-density tissue microarray and immunohistochemistry. Modern Pathology 2004;17(4):430-9.

Tan D, Wiseman S, Zhou Y, Li Q, Ward P, Slocum HK, Alrawi S, Loree T, Hicks W, Rigual N, Anderson G, Stoler D. Definition of a region of loss of heterozygosity at chromosome 11q23.3-25 in head and neck squamous cell carcinoma using laser capture microdissection technique. Diagnostic Molecular Pathology 2004;13(1):33-40.

Azrak RG, Cao S, Slocum HK, Tóth K, Durrani FA, Yin M-, Pendyala L, Zhang W, McLeod HL, Rustum YM. Therapeutic synergy between irinotecan and 5-fluorouracil against human tumor xenografts. Clinical Cancer Research 2004;10(3):1121-9.

Tan D, Deeb G, Wang J, Slocum HK, Winston J, Wiseman S, Beck A, Sait S, Anderson T, Nwogu C, Ramnath N, Loewen G. HER-2/neu protein expression and gene alteration in stage I-IIIA non-small-cell lung cancer: A study of 140 cases using a combination of high throughput tissue microarray, immunohistochemistry, and fluorescent in situ hybridization. Diagnostic Molecular Pathology 2003;12(4):201-11.

White DB, Slocum HK, Brun Y, Wrzosek C, Greco WR. A new nonlinear mixture response surface paradigm for the study of synergism: A three drug example. Current Drug Metabolism 2003;4(5):399-409.

Faessel HM, Slocum HK, Rustum YM, Greco WR. Thymidine and hypoxanthine protection patterns of the folic acid-enhanced synergies for combinations of trimetrexate plus a polyglutamylatable inhibitor of purine or thymidylate synthesis against human ileocecal HCT-8 cells. International Journal of Oncology 2003;23(2):401-9.

Tan D, Li Q, Deeb G, Ramnath N, Slocum HK, Brooks J, Cheney R, Wiseman S, Anderson T, Loewen G. Thyroid transcription factor-1 expression prevalence and its clinical implications in non-small cell lung cancer: A high-throughput tissue microarray and immunohistochemistry study. Human Pathology 2003;34(6):597-604

Tan D, Kirley S, Li Q, Ramnath N, Slocum HK, Brooks JS, Wu C-, Zukerberg LR. Loss of cables protein expression in human non-small cell lung cancer: A tissue microarray study. Human Pathology 2003;34(2):143-9.

Ghadersohi A, Chitta K, Greco WR, Harvey S, Winston J, Slocum H, Odunsi K, Sood AK. Tumor antigens and markers for breast and ovarian cancers. Front Biosci 2002;7:e48-57.

Slocum HK, Parsons JC, Winslow EO, Broderick L, Minderman H, Tóth K, Greco WR, Rustum YM. Time-lapse video reveals immediate heterogeneity and heritable damage among human ileocecal carcinoma HCT-8 cells treated with raltitrexed (ZD1694). Cytometry 2000;41(4):252-60.

Yin M-, Guo B, Vanhoefer U, Azrak RG, Minderman H, Frank C, Wrzosek C, Slocum HK, Rustum YM. Characterization of protein kinase chk1 essential for the cell cycle checkpoint after exposure of human head and neck carcinoma A253 cells to a novel topoisomerase I inhibitor BNP1350. Molecular Pharmacology 2000;57(3):453-9.

Gibbs JF, Slocum HK, Cao S, Rustum YM. Image analysis for quantitation of solid tumor drug sensitivity. International Journal of Surgical Investigation 1999;1(2):133-8.

Yin M-, Tóth K, Cao S, Guo B, Frank C, Slocum HK, Rustum YM. Involvement of cyclin D1-CDK5 overexpression and MCM3 cleavage in bax- associated spontaneous apoptosis and differentiation in an A253 human head and neck carcinoma xenograft model. International Journal of Cancer 1999;83(3):341-8.

Sharma M, Slocum HK. Prevention of quinone-mediated DNA arylation by antioxidants. Biochemical and Biophysical Research Communications 1999;262(3):769-74.

Faessel HM, Levasseur LM, Slocum HK, Greco WR. Parabolic growth patterns in 96-well plate cell growth experiments. In Vitro Cellular and Developmental Biology - Animal 1999;35(5):270-8.

Faessel HM, Slocum HK, Rustum YM, Greco WR. Folic acid-enhanced synergy for the combination of trimetrexate plus the glycinamide ribonucleotide formyltransferase inhibitor 4-[2-(2-amino-4-oxo-4,6,7,8-tetrahydro-3H-pyrimidino[5,4,6][1,4]thiazin-6-yl) -(S)ethyl]-2,5-thienoylamino-L-glutamic acid (AG2034). comparison across sensitive and resistant human tumor cell lines. Biochemical Pharmacology 1999;57(5):567-77.

Yin M-, Guo B, Panadero A, Frank C, Wrzosek C, Slocum HK, Rustum YM. Cyclin E-Cdk2 activation is associated with cell cycle arrest and inhibition of DNA replication induced by the thymidylate synthase inhibitor tomudex. Experimental Cell Research 1999;247(1):189-99.

Cao S, Lu K, Tóth K, Slocum HK, Shirasaka T, Rustum YM. Persistent induction of apoptosis and suppression of mitosis as the basis for curative therapy with S-1, an oral 5-fluorouracil prodrug in a colorectal tumor model. Clinical Cancer Research 1999;5(2):267-74.